Bladder cancer - Articles and news items


AstraZeneca’s bladder cancer treatment receives FDA approval

Industry news / 3 May 2017 / Niamh Marriott, Junior Editor

The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca’s Imfinzi (durvalumab) to treat metastatic urothelial carcinoma…

Global urological cancers market to double by 2022, says GBI Research

Industry news / 30 June 2016 / Victoria White, Digital Content Producer

The urological cancers market will increase from $17.9 billion in 2015 to $35.9 billion by 2022, according to business intelligence provider GBI Research…

Tecentriq to dominate the bladder cancer market, says GlobalData

Industry news / 14 June 2016 / Victoria White, Digital Content Producer

The launch of Roche’s Tecentriq will usher in a dramatic change in the treatment paradigm of bladder cancer, according to an analyst with GlobalData…

FDA grants priority review to Roche’s atezolizumab in urothelial carcinoma

Industry news / 15 March 2016 / Victoria White

The priority review is based on results of the IMvigor 210 study that evaluated the safety and efficacy of atezolizumab in people with locally advanced or metastatic urothelial carcinoma, regardless of PD-L1 expression.

Bladder cancer treatment market set to boom, says GlobalData

Industry news / 14 January 2016 / Victoria White

The company states that the growth will be primarily down to the introduction of Telesta Therapeutics MCNA and Roche’s atezolizumab in 2016 and Bristol-Myers Squibb’s Opdivoin 2017…

Roche presents updated results for atezolizumab in mUC

Industry news / 8 January 2016 / Victoria White

Median overall survival from the updated study results was 11.4 months in people with higher levels of PD-L1 expression, and 7.9 months in the overall study population…

Personalised peptide vaccine increased bladder cancer survival in study

Industry news / 18 November 2015 / Victoria White

The median overall survival for patients assigned personalised peptide vaccine and best-supportive care was almost twice as long as that for patients assigned best-supportive care…

Ramucirumab improves progression-free survival in bladder cancer trial

Industry news / 28 September 2015 / Victoria White

Median progression-free survival was 5.4 months on the ramucirumab-docetaxel arm as compared to 2.8 months for patients treated with docetaxel alone…

Atezolizumab could spur bladder cancer treatment innovation

Industry news / 28 July 2015 / Victoria White

Atezolizumab is poised to become a major bladder cancer therapy in the race for FDA approval, following its promising performance in recent Phase II trials…


Atezolizumab shrank tumours in people with a specific type of bladder cancer in Phase II study

Industry news / 13 July 2015 / Victoria White

In the Phase II IMvigor 210 study, Roche’s atezolizumab shrank tumours in people with locally advanced or metastatic urothelial bladder cancer (UBC)…


NICE publishes bladder cancer guideline, recommending photodynamic diagnosis to improve detection

Industry news / 2 March 2015 / Photocure ASA

Photocure ASA, a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to announce that the National Institute for Health and Care Excellence (NICE) in the UK has published its first guidelines on bladder cancer, recommending photodynamic diagnosis for improved detection of bladder cancer…


Masters Speciality Pharma signs exclusivity agreement with Speciality European Pharma for the exclusive distribution of Mitocin®/Mitem® 20mg (mitomycin)

Industry news / 23 October 2014 / Masters Speciality Pharma

Masters Speciality Pharma is pleased to announce a partnership agreement with Speciality European Pharma for the exclusive distribution of Mitocin®/Mitem® (mitomycin) to the Caribbean, Egypt, Kuwait, Iran, Saudi Arabia, UAE, Kenya, Seychelles, Uganda, Zimbabwe, Chile, Denmark, Greece, Ireland, Norway and Sweden…

  • Page 1 of 2
  • 1
  • 2
  • >


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...